Christina Gersch
University of Michigan
H-index: 13
North America-United States
Top articles of Christina Gersch
Attempted replication of pharmacogenetic association of variants in PPP1R14C and CCDC148 with aromatase inhibitor-induced musculoskeletal symptoms
Pharmacogenetics and Genomics
2024/2/8
Discovery of ERD-3111 as a Potent and Orally Efficacious Estrogen Receptor PROTAC Degrader with Strong Antitumor Activity
Journal of Medicinal Chemistry
2023/8/30
Effects of CYP3A4 and CYP2C9 genotype on systemic anastrozole and fulvestrant concentrations in SWOG S0226
Pharmacogenomics
2023/8
Impact of pharmacogenetics on intravenous tacrolimus exposure and conversions to oral therapy
Transplantation and Cellular Therapy
2022/1/1
Osteonecrosis of the jaw risk factors in bisphosphonate‐treated patients with metastatic cancer
Oral diseases
2022/1
Daniel L Hertz
H-Index: 20
Christina Gersch
H-Index: 9
Dafydd Thomas
H-Index: 45
Mousumi Banerjee
H-Index: 40
James M Rae
H-Index: 32
Genome-wide association study of aromatase inhibitor discontinuation due to musculoskeletal symptoms
Supportive Care in Cancer
2022/10
Results: A total of 143 participants with PRO and genetic data were included in this analysis, most of whom were treated with anastrozole (78%) or letrozole (20%). On primary …
Pharmacogenomics of Adverse Drug Reactions (ADRs)
2022/4/1
PD-L1 expression on circulating tumor cells and platelets in patients with metastatic breast cancer
PLoS One
2021/11/15
Genome-wide association study of letrozole plasma concentrations identifies non-exonic variants that may affect CYP2A6 metabolic activity
Pharmacogenetics and genomics
2021/7/1
Further evidence that OPG rs2073618 is associated with increased risk of musculoskeletal symptoms in patients receiving aromatase inhibitors for early breast cancer
Frontiers in Genetics
2021/6/15
Evaluating the impact of CYP3A5 genotype on post-transplant healthcare resource utilization in pediatric renal and heart transplant recipients receiving tacrolimus
Pharmacogenomics and personalized medicine
2021/3/12
Abstract PS5-25: Association of OPG rs2073618 and aromatase inhibitor induced musculoskeletal symptoms
Cancer Research
2021/2/15
Short-term CDK4/6 inhibition radiosensitizes estrogen receptor–positive breast cancers
Clinical Cancer Research
2020/12/15
Radiosensitization of Estrogen Receptor Positive Breast Cancers with Short-Term CDK4/6 Inhibition
International Journal of Radiation Oncology, Biology, Physics
2020/11/1
CDK4/6 inhibitor-mediatated radiosensitization of estrogen receptor positive breast cancer
Cancer Research
2020/8/15
Genetic variation in Charcot–Marie–Tooth genes contributes to sensitivity to paclitaxel-induced peripheral neuropathy
Pharmacogenomics
2020/8
Genome-wide association study of steady-state letrozole concentration in patients with breast cancer.
2020/5/20
Genetic variation in EPHA contributes to sensitivity to paclitaxel‐induced peripheral neuropathy
British Journal of Clinical Pharmacology
2020/5
Targeted degradation of activating estrogen receptor alpha ligand-binding domain mutations in human breast cancer (vol 15, pg 854, 2019)
Breast Cancer Research and Treatment
2020/4
EPHA5 RS7349683 IS NOT ASSOCIATED WITH CIPN-SENSITIVITY IN LUNG CANCER PATIENTS RECEIVING PACLITAXEL TDM.
2020
